PEBC Report - Programa de Epigenética y Biología del Cáncer

Foreword by Emilià Pola,
IDIBELL General Director
T
he Bellvitge Biomedical Research Institute – IDIBELL is an emerging
research institution where medicine meets with research for a
better understanding of patients needs and diseases of all sorts. With
a dedicated team of more than 500 researchers, IDIBELL has a committment
to address relevant clinical problems to bring about significant
improvements in health an quality of life. Our research is based
on the activity of the two partner hospitals (Bellvitge University
Hospital and Catalan Institute of Oncology) and consequently has a
very wide scope, ranging from epidemiology to infectious diseases,
organ transplantation and immunology, human genetics, neurology,
metabolic diseases and cancer in its very diverse forms.
The Cancer Epigenetics and Biology Program (PEBC) is the most
recent addition to our the scientific activity, and helps to keep IDIBELL
at the forefront of global biomedical research. The emerging discipline
of epigenetics is ushering in a new paradigm that significantly
expands our understanding of genes and their interaction with the environment, shedding new light
on many biological and medical challenges.
It is for me a pleasure and a privilege to host the symposium and to welcome you all to this exciting
opportunity to discuss and to participate in one of the hottest and most rapidly developing fields
of modern biology and medicine.
Emilià Pola
General Director IDIBELL
Cancer Epigenetics and Biology Symposium
4 28, 29 May 2009, Barcelona